Laurus Labs Limited (LAURUSLABS) share price and analysis
LAURUSLABS last traded at ₹2,338.00 (+5.32%) on the NSE. Market cap ₹1,26,325 Cr (Large cap), Pharma & Healthcare sector.
Overall rating: 7.3/10 (Good)
- Valuation: 3.3/10
- Profitability: 8.9/10
- Growth: 10.0/10
- Financial health: 5.0/10
- Price trend: 9.3/10
Long-term view: Good for long-term. More strengths than weaknesses for a multi-year hold. Trade bias (next few weeks): Strong long. Trend and momentum are clearly pointing up.
Strengths of LAURUSLABS
- Return on equity (24.0%): Earns ₹24 profit for every ₹100 of shareholder capital, which is excellent capital efficiency.
- Long-term trend (+53.7% vs 200-DMA): Trading well above its 200-day average, a clear long-term uptrend.
- Revenue growth (YoY) (+33.4%): Sales are growing fast.
- Profit growth (YoY) (+126.0%): Profits are growing rapidly.
- 50-DMA vs 200-DMA (+37.4% gap): 50-day average is above the 200-day (golden-cross setup), so medium-term momentum is up.
- 6-month performance vs Nifty 50 (+76.6% vs +7.4%): Strongly outperforming the Nifty 50 over 6 months.
- Price vs growth (PEG) (PEG 0.75): Price looks cheap for how fast profits are growing.
- Debt / equity (0.42): Comfortable debt level.
- Net profit margin (17.1%): Healthy profit margins.
- 52-week range (6% below high): Trading near its 52-week high, so buyers are in control.
- Momentum (RSI 14) (RSI 57): Mildly positive momentum.
Weaknesses of LAURUSLABS
- Valuation (P/E) (P/E 94.4 vs sector 41.1): Expensive at 2.3× the sector median P/E. High expectations are already priced in.
- Free cash flow (Negative): Burning cash, because free cash flow is negative. Growth is being funded by debt, equity or reserves.
- Analyst target (₹2,156 (-7.8%)): 14 analysts' average target implies -7.8%. The stock is already above where most analysts see it.
Key numbers
| Number | Value | Assessment | Normal range |
|---|---|---|---|
| P/E (TTM) | 94.4 | Expensive vs peers | 37.0–49.3 (sector median 41.1) |
| Forward P/E | 66.0 | Growth expected, but still pricey | below today's P/E (94.4) and near 41 |
| Price / book | 20.85 | High | 6–12 (high ROE allows more) |
| EPS (TTM) | ₹24.78 | Profitable | above ₹0 |
| Return on equity | 24.0% | Strong | 15%+ (below 10% is weak) |
| Debt / equity | 0.42 | Low debt | below 1.0 (under 0.5 is great) |
| Net margin | 17.1% | Healthy | 10%+ (below 5% is thin) |
| Operating margin | 24.1% | Strong | 20%+ strong, below 10% thin |
| Revenue growth | +33.4% | Growing well | 10%+ a year (below 3% is weak) |
| Profit growth | +126.0% | Growing well | 10%+ a year (falling is weak) |
| Dividend yield | 0.09% | Small payout | 1.5%+ (none is fine for growth firms) |
| Current ratio | 1.31 | Adequate | 1.5+ (below 1 is tight) |
| 52W high | ₹2,488.00 | 6% below · near the high | price in the top 40% of its 52-week range |
| 52W low | ₹917.95 | Price is 155% above it | |
| 50-DMA | ₹2,090.95 | Price 11.8% above | price above it = short-term uptrend |
| 200-DMA | ₹1,521.34 | Price 53.7% above | price above it = long-term uptrend |
| 1Y return | +133.6% | Beat the Nifty 50 | Nifty 50 did −0.4% |
| Beta | 0.22 | Steadier than the market | 0.8–1.3 (1 = moves with market) |
| Promoter / insider | 32.0% | Moderate stake | 50%+ shows owner commitment |
| Institutions | 35.0% | Strong big-investor interest | 30%+ is strong |
| Analyst target | ₹2,156.29 | 7.8% downside · 14 analysts | 8%+ upside |
Questions about LAURUSLABS
What is the share price of Laurus Labs Limited (LAURUSLABS) today?
LAURUSLABS last traded at ₹2,338.00 (+5.32% on the day) on the NSE. Its 52-week range is ₹917.95 to ₹2,488.00. Prices are delayed and come from Yahoo Finance.
Is LAURUSLABS a good stock for the long term?
StockLens rates LAURUSLABS 7.3 out of 10 (Good) overall. Its long-term verdict is "Good for long-term": More strengths than weaknesses for a multi-year hold. Strengths: high ROE, uptrend, revenue growth. Concerns: expensive vs peers, cash burn, above analyst targets.
Is LAURUSLABS share overvalued?
LAURUSLABS trades at a P/E of 94.4 against a Pharma & Healthcare median of 41.1, which StockLens rates as "Expensive vs peers". Its price-to-book ratio is 20.85.
Is LAURUSLABS good for short-term trading?
The trade bias for the next few weeks is "Strong long": Trend and momentum are clearly pointing up. The price is 53.7% above its 200-day average and 14-day RSI is 57.
Which stocks are similar to LAURUSLABS?
Similar Pharma & Healthcare stocks of comparable size include Apollo Hospitals, Zydus Lifesciences, Dr. Reddy's Laboratories, Cipla, Aurobindo Pharma. You can compare up to 4 of them side by side on StockLens.
About Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
Stocks similar to LAURUSLABS
- Apollo Hospitals share price
- Zydus Lifesciences share price
- Dr. Reddy's Laboratories share price
- Cipla share price
- Aurobindo Pharma share price
- Max Healthcare share price
Compare LAURUSLABS with APOLLOHOSP, ZYDUSLIFE, DRREDDY
Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.